Russia’s ChemRar reports positive data of Favipiravir in Covid-19

14th May 2020 (Last Updated May 14th, 2020 11:32)

ChemRar Group and The Russian Direct Investment Fund (RDIF) have reported positive data from a multi-centre clinical trial of Favipiravir in patients hospitalised due to Covid-19.

Russia’s ChemRar reports positive data of Favipiravir in Covid-19
3D print of a SARS-CoV-2—also known as 2019-nCoV, the virus that causes COVID-19—virus particle. Credit: NIH.

ChemRar Group and The Russian Direct Investment Fund (RDIF) have reported positive data from a multi-centre clinical trial of Favipiravir in patients hospitalised due to Covid-19.

During the randomised, open, comparative trial, 40 patients were treated with the drug. Of these patients, 60% tested negative for coronavirus following five days of treatment, two times higher compared to those on standard therapy.

The findings are said to be consistent with data from studies performed in China, which also revealed a decrease in the disease duration from 11 days to four-five days.

ChemRar Pharma CEO Elena Yakubova said: “The Safety Council has held a meeting today as part of the clinical trial of Favipiravir. Independent experts discussed the effectiveness of the first five days of the therapy and confirmed the sufficient safety and tolerability of the drug, as well as recommending continued clinical trial.

“We are actively opening additional medical centres in Moscow and other Russian cities, but as part of the trial we can cover a limited number of patients.”

Six medical centres in Moscow, Smolensk and Nizhny Novgorod are currently conducting trials, including IM Sechenov First Moscow State Medical University, Lomonosov Moscow State University, and the Central Clinical Hospital.

A total of 30 medical centres across eight regions in Russia will enrol 330 patients.

Russian Direct Investment Fund CEO Kirill Dmitriev said: “The first positive results of the trial will facilitate an accelerated permission from the Ministry of Health of the Russian Federation to start using the drug, which will enable treatment of patients with Favipiravir across Russia’s regions.

“The use of the drug will help reduce the length of stay in a hospital for patients infected with Covid-19 and the need for opening new hospitals.”

Dmitriev added that 250 treatment courses of the drug have been produced, with an additional 1,500 courses in the production stage. In alliance with ChemRar, lines have been established to produce up to 600,000 courses per year.

ChemRar and RDIF will now seek a registration certificate to potentially use Favipiravir across the country. The partners expect to begin commercial deliveries of the drug by the end of this month.